Plain-English translation of NCT06931626 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This study is testing a new drug called paired with chemotherapy (a medicine called ) in people whose small cell lung cancer has come back after earlier treatments. Researchers want to understand if this medication combination is safe, how well it works against the cancer, and how your body processes it.
Small cell lung cancer is aggressive and often comes back even after initial treatment. Doctors need new options for patients whose cancer has returned, especially those who have already tried multiple previous therapies. This medication is being studied because it may work differently than other available treatments.
You likely qualify if…
You likely don't qualify if…
You would take by mouth twice daily for 28 days in a row, along with chemotherapy pills taken by mouth on days 1–5 of each 28-day cycle. The study is small (recruiting about 10 patients) and open-label, meaning you'll know you're receiving this medication combination. You'll have regular visits for safety checks, blood work, and imaging scans to see how the cancer is responding.
AI-generated summary from trial data · Aug 12, 2026 · Not medical advice
United States